Enfortumab vedotin and pembrolizumab combination offers transformative benefits, doubling median progression-free and overall survival in advanced urothelial carcinoma. The EV-302 trial showed a 74% ...

The FDA has approved a before and after surgery regimen for pembrolizumab to improve outcomes in resectable locally-advanced head and neck squamous cell carcinoma (HNSCC). Specifically, the new ...

For most patients with clinical stage I-II deficient mismatch repair (dMMR) colon cancer, a single cycle of neoadjuvant pembrolizumab may be sufficient to achieve a pathologic complete response, ...